SAN FRANCISCO — When it comes to confronting disappointing news, Medtronic (Minneapolis) CEO Omar Ishrak is not one to beat around the proverbial bush. At the 32nd annual J.P. Morgan Healthcare Conference in San Francisco, Ishrak made a point to address upfront the recent news that the company's U.S. pivotal trial in renal denervation for treatment-resistant hypertension failed to meet its primary efficacy endpoint. Read More
